Influence of electric charge variation at residues 209 and 159 on the interaction of eIF4E with the mRNA 5' terminus.
Eukaryotic translation initiation factor 4E (eIF4E) is essential for efficient protein synthesis in cap-dependent translation. The protein specifically binds the cap structure at the mRNA 5' terminus and facilitates the assembly of the mRNA with other initiation factors and the 40S ribosomal subunit. Phosphorylation of eIF4E is implicated in the regulation of the initiation step of translation. However, the molecular mechanism of this regulation still remains unclear. To address this problem, we have determined the binding affinities of eIF4E specifically mutated at position 209 or 159 for a series of novel mono- and dinucleotide cap analogues by a fluorometric time-synchronized titration method. A 1.5-3-fold reduction in the affinity of cap for the S209E mutant and a 1-2-fold increase in the affinity of cap for the S209K mutant, depending on the negative charge of phosphate chains, indicate that phosphorylation at Ser209 creates electrostatic repulsion between the protein and the negatively charged cap structure. The inhibition of the ability to bind cap analogues by the K159A mutant and its phosphorylated counterpart shows significant participation of Lys159 in the binding of the capped mRNA. Both structural modifications, phosphorylation and the replacement of lysine with alanine, result in an increase in the negative Gibbs free energy of association that is proportional to the length of the cap phosphate chain and additive, i.e., equal to the sum of the individual destabilizing changes of DeltaG degrees. The possible implication of these results for the mechanism of control of eIF4E by phosphorylation, especially for the "clamping model", is discussed.
Zuberek
Joanna
J
Department of Biophysics, Institute of Experimental Physics, Warsaw University, 93 Zwirki i Wigury Street, 02-089 Warsaw, Poland.
Jemielity
Jacek
J
Jablonowska
Agnieszka
A
Stepinski
Janusz
J
Dadlez
Michał
M
Stolarski
Ryszard
R
Darzynkiewicz
Edward
E
D000409:Alanine / Q000235:genetics; D000818:Animals; D001667:Binding, Competitive / Q000235:genetics; D039561:Eukaryotic Initiation Factor-4E / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D006151:Guanosine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000378:metabolism; D006158:Guanosine Pentaphosphate / Q000138:chemical synthesis / Q000378:metabolism; D006159:Guanosine Tetraphosphate / Q000138:chemical synthesis / Q000378:metabolism; D006801:Humans; D008239:Lysine / Q000235:genetics; D051379:Mice; D009690:Nucleic Acid Conformation; D010766:Phosphorylation; D010768:Phosphoserine / Q000378:metabolism; D011485:Protein Binding / Q000235:genetics; D012315:RNA Caps / Q000138:chemical synthesis / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism*; D012996:Solutions; D055672:Static Electricity; D013816:Thermodynamics
D039561:Eukaryotic Initiation Factor-4E; D012315:RNA Caps; D012333:RNA, Messenger; D012996:Solutions; D006151:Guanosine; D010768:Phosphoserine; C016578:7-methylguanosine; D006159:Guanosine Tetraphosphate; D006158:Guanosine Pentaphosphate; D008239:Lysine; D000409:Alanine